ScholarIQanswers from OpenAlex & ORCID
Christophe Louvet
ResearcherPublications, citations & collaboration network
Christophe Louvet is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Christophe Louvet have?
ScholarIQindexed works
Christophe Louvet has 498 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Christophe Louvet have?
ScholarIQcitation count
Christophe Louvet has 29,803 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Christophe Louvet?
ScholarIQh-index
Christophe Louvet has an h-index of 69 in OpenAlex.
What is the i10-index of Christophe Louvet?
ScholarIQi10-index
Christophe Louvet has an i10-index of 186 in OpenAlex.
What is the ORCID of Christophe Louvet?
ScholarIQorcid
The ORCID for Christophe Louvet is on the source record.
What is the OpenAlex record for Christophe Louvet?
ScholarIQopenalex
The OpenAlex for Christophe Louvet is on the source record.
What are the most-cited papers on Christophe Louvet?
ScholarIQmost cited works
Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies
F. Huguet, Thierry André, Pascal Hammel, Pascal Artru, Jacques Balosso, Frédèric Selle, Élisabeth Deniaud-Alexandre, Philippe Ruszniewski, E. Touboul, Roberto Labianca, Aimery de Gramont, Christophe Louvet
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
Benoist Chibaudel, Frédérique Maindrault‐Gœbel, Gérard Lledo, Laurent Mineur, Thierry André, Mostepha Bennamoun, May Mabro, Pascal Artru, Élisabeth Carola, M. Flesch, Olivier Dupuis, Philippe Colin, Annette K. Larsen, Pauline Afchain, Christophe Tournigand, Christophe Louvet, Aimery de Gramont
Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial
Thierry André, Déwi Vernerey, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Roger Faroux, Serge Fratté, Marine Hug de Larauze, Sophie Paget‐Bailly, Benoist Chibaudel, Jérémie Bez, Jérôme Dauba, Christophe Louvet, Céline Lepère, Olivier Dupuis, Y. Bécouarn, May Mabro, Joëlle Egreteau, Olivier Bouché, G. Deplanque, Marc Ychou, Marie Pierre Galais, François Ghiringhelli, Louis Marie Dourthe, Jean‐Baptiste Bachet, Ahmed Khalil, Franck Bonnetain, Aimery de Gramont, Julien Taı̈eb, for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER